|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit. The European Medicines Agency said its ...
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.